VRCA
What one share of Verrica Pharmaceuticals holds
Pharmaceutical Preparations
We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need.
Verrica Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.83 |
|---|---|
| Profit | −$1.88 |
| Cash and investments | $0.65 |
| Debt | $0.06 |
| Book value | $0.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$15.64 | — | −$16.08 | — | −$19.03 |
| 2018 | — | −$14.08 | $0.53 | −$12.72 | — | $34.79 |
| 2019 | — | −$11.33 | $0.27 | −$11.28 | — | $25.21 |
| 2020 | — | −$17.08 | $0.59 | −$12.67 | — | $12.97 |
| 2021 | $4.44 | −$12.97 | $0.33 | −$10.53 | — | $11.85 |
| 2022 | $2.64 | −$7.17 | $0.09 | −$5.55 | — | $9.74 |
| 2023 | $1.13 | −$14.78 | $0.08 | −$8.59 | — | $4.66 |
| 2024 | $1.46 | −$14.78 | $0.01 | −$11.77 | — | −$1.07 |
| 2025 | $3.34 | −$1.68 | $0.00 | −$1.65 | — | $1.44 |